RECOMBINANT VIRUS-LIKE PARTICLES (VLP) USING A PROTEIN OF THE BOVINE IMMUNODEFICIENCY VIRUS GROUP ANTIGEN (GAG) Russian patent published in 2021 - IPC C12N7/01 A61K39/145 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology, namely to a vaccine for stimulating an immune response to target pathogens, containing a virus-like particle (VLP) based on a protein of the bovine immunodeficiency virus group antigen (Bgag), wherein the Bgag VLP comprises one or several different target pathogen proteins. Produced is a transfer vector plasmid for producing a vaccine, containing the bovine immunodeficiency virus gag gene ("Bgag gene"), one or several genes encoding one or several different target pathogen proteins, and one or more promoters, wherein said one or several genes encoding target pathogen proteins comprise a gene encoding a trans-membrane protein. Claimed is a method for preventing or suppressing the disease caused by the target pathogen in an animal by introducing an effective amount of vaccine. Claimed is a method for producing a vaccine for stimulating an immune response to the target pathogens, including the following stages: cloning the transfer vector of the described Bgag gene and the described gene encoding a target pathogen protein into a plasmid, wherein each gene is controlled by a promoter; preparing a carrier virus using said transfer vector plasmid; infecting a eukaryotic cell with said carrier virus to create the Bgag VLP; mixing an effective amount of the produced Bgag VLP with one or several adjuvants suitable for administration of the vaccine. Claimed is a method for identifying patients previously injected with the vaccine. The method includes the stages of measuring whether the Bgag gene or the Bgag protein is present in the patient and correlating a previous vaccination with the presence of the Bgag gene or the Bgag protein.

EFFECT: invention provides a possibility to produce a vaccine containing recombinant virus-like particles (VLP) of a protein of the bovine protein immunodeficiency virus group antigen ("Bgag") containing one or several different types of target pathogen proteins.

42 cl, 2 tbl, 41 dwg, 21 ex